AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33250314
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day Oligopin®
Trial: 35936217
Drug: Acetyl-L-Carnitine (ALC)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-Carnitine (ALC) 1000 mg three times per day for three consecutive days
Trial: 35445808
Drug: Combined CPAP
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined CPAP and tolterodine treatment
Trial: 35445808
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment only
Trial: 39699848
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine U300
Trial: 34051544
Drug: Immediate reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate reduction from 15.5 to 0.4 mg of nicotine per gram of tobacco (mg/g)
Trial: 34051544
Drug: Gradual reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual reduction to 0.4 mg/g
Trial: 34051544
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with normal nicotine cigarettes (15.5 mg/g)
Trial: 34328109
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (500 mg capsule containing Lactobacillus acidophilus LA1, Bifidobacterium longum sp54 cs, and Bifidobacterium bifidum sp9 cs)
Trial: 32214139
Drug: Epidural bolus
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bolus (0.15% ropivacaine 0.3 ml·kg‐1)
Trial: 32214139
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (0.15% ropivacaine 0.3 ml·kg‐1)
Trial: 32070793
Drug: Early Manual
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early Manual Therapy Group (EMTG)
Trial: 36343423
Drug: Rosemary capsules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosemary capsules, 1 capsule twice a day for 8 weeks
Trial: 36343423
Drug: Placebo, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 capsule twice a day for 8 weeks
Trial: 33066761
Drug: Pyridostigmine bromide
RxNorm normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridostigmine bromide 60 mg/day P.O.
Trial: 35039300
Drug: LEGO-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEGO-based therapy
Trial: 34362303
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg 10% IVIG administered every two weeks for five doses
Trial: 34362303
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline administered every two weeks for five doses (control)
Trial: 35550645
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT-SAD)
Trial: 34018057
Drug: Machine Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine Learning (ML) using a random forest algorithm trained on 10 features extracted from ultrasound images.
Trial: 34018057
Drug: Machine Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine Learning (ML) aiding a breast radiologist.
Trial: 34018057
Drug: Breast radiologist
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast radiologist without ML assistance.
Trial: 35686864
Drug: Combined ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined ultrasound guided peritendinous hyaluronic acid (HA) injection with extracorporeal shock waves therapy (E‐g)
Trial: 35686864
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock waves therapy only (SC‐g)
Trial: 33616478
Drug: HL02 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HL02 (6 mg/kg)
Trial: 32422942
Drug: UDCA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA treatment (100 mg three times per day for two months)
Trial: 33044102
Drug: Acarbose test
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose test formulation (T)
Trial: 33683313
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (systolic blood pressure goal <120 mm Hg)
Trial: 33683313
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (systolic blood pressure goal <140 mm Hg)
Trial: 33683313
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between intensive and standard treatment
Trial: 36229224
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rhEpo) treatment, 9 IU × kg bw−1, injected three times per week for 4 weeks
Trial: 36229224
Drug: Blood transfusions,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood transfusions, 130 ml red blood cells infused
Trial: 34663787
Drug: Engage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engage therapy
Trial: 33813244
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of sucrose (S10)
Trial: 33813244
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of sucrose (S15)
Trial: 35997816
Drug: CC (Usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC (Usual Community Care)
Trial: 35064876
Drug: Subjective titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjective titration
Trial: 35064876
Drug: PSG-guided titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSG-guided titration using RCMP
Trial: 35064876
Drug: DISE-assisted titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DISE-assisted titration using RCMP
Trial: 36120593
Drug: OEA 300
RxNorm normalized name: OEA
DrugBank: Oleic monoethanolamide (DB16495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OEA 300 mg/day
Trial: 36120593
Drug: OEA 600
RxNorm normalized name: OEA
DrugBank: Oleic monoethanolamide (DB16495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OEA 600 mg/day
Trial: 34498388
Drug: BISO/RAMI 10/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BISO/RAMI 10/5 mg
Trial: 34498388
Drug: BISO/RAMI 10/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BISO/RAMI 10/10 mg
Trial: 34498388
Drug: BISO 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BISO 10 mg and RAMI 10 mg (single doses)
Trial: 33928903
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (loading dose 1 g over 10 minutes then infusion of 1 g over 8 hours)
Trial: 32529206
Drug: Oily fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oily fish (∼300 g/wk)
Trial: 34717041
Drug: givosiran (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: givosiran (2.5 mg/kg monthly)
Trial: 33052789
Drug: Topical scar
RxNorm normalized name: Mederma Advanced Scar Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical scar gel containing Allium cepa extract, allantoin and heparin, applied postoperatively for 6 months.
Trial: 35259918
Drug: Invasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive treatment strategy (INV)
Trial: 35292055
Drug: Qingre Lishi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingre Lishi Decoction (QLRD) - 'heat-clearing and diuresis-promoting' prescription
Trial: 35292055
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment and colchicine tablets (Control)
Trial: 34813986
Drug: Fully Integrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully Integrated Treatment (FIT) for comorbid SAD and AUD IOP
Trial: 33789524
Drug: H1-receptor antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H1-receptor antagonists (H1RAs)
Trial: 33091192
Drug: On-demand inhaled
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand inhaled interferon beta-1a (AZD9412)
Trial: 35872235
Drug: IVPCA (Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVPCA (Intravenous Patient-Controlled Analgesia)
Trial: 35872235
Drug: On-demand administration
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand administration (oral, intramuscular, or intravenous)
Trial: 34183341
Drug: TRiP(cast) score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRiP(cast) score based thromboprophylactic anticoagulant treatment for patients with a score ≥7
Trial: 35819423
Drug: Pharmacogenomic-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenomic-guided treatment (n=966)
Trial: 35819423
Drug: Pharmacogenomic-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenomic-guided treatment
Trial: 36100350
Drug: Continuous ixekizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ixekizumab treatment
Trial: 34750069
Drug: Twice per
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice per week heat training (HT2)
Trial: 32635999
Drug: Regular clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular clinical treatment for OA
Trial: 34975131
Drug: Dexmedetomidine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.75 μg/kg intravenous over 10 min
Trial: 34975131
Drug: Midazolam 0.035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.035 mg/kg intravenous over 1 min
Trial: 39511836
Drug: Testosterone Replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone Replacement Therapy (TRT)
Trial: 35085506
Drug: Pyrotinib 400
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib 400 mg orally once daily and capecitabine 1000 mg/m2 orally twice daily for 14 days, followed by 7 days off every 3 weeks until disease progression or unacceptable toxicity.
Trial: 34756613
Drug: 2008-2009 seasonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2008-2009 seasonal inactivated trivalent influenza vaccine (TIV)
Trial: 34756613
Drug: Control hepatitis
RxNorm normalized name: hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control hepatitis A (HepA) vaccine
Trial: 35966870
Drug: Intrathecal pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal pethidine (10 mg) with bupivacaine (12.5 mg)
Trial: 35966870
Drug: Bupivacaine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (12.5 mg) alone
Trial: 33438085
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (100 mL of orange juice with 12 g carrot and 2.5 g of turmeric) three times per week for three months
Trial: 33400078
Drug: Supplemental education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental education explaining the rationale behind recommendations to delay fertility treatments due to the COVID‐19 pandemic
Trial: 32201918
Drug: Body weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body weight-based prednisolone regimen (2 mg/kg/day till remission, then 1.5 mg/kg on alternate days for 4 weeks)
Trial: 32201918
Drug: Body surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body surface area-based prednisolone regimen (60 mg/m2/day till remission, then 40 mg/m2 on alternate days for 4 weeks)
Trial: 35487525
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg orally for 6 months
Trial: 34950731
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (1.5 g, LCG)
Trial: 34950731
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose (3.0 g, MCG)
Trial: 34950731
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (6.0 g, HCG)
Trial: 34950731
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (1.5 g, 3.0 g, 6.0 g)
Trial: 33753432
Drug: Integration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integration of a pharmacist within general practice teams to optimise prescribing and medication-related activities.
Trial: 32366238
Drug: Self-medication behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-medication behavior
Trial: 32366238
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of OTC drugs
Trial: 32366238
Drug: Awareness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Awareness of risks of self-medication
Trial: 32366238
Drug: Health issues
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health issues leading to self-medication
Trial: 32366238
Drug: Types of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Types of medication used
Trial: 32366238
Drug: Sources of
RxNorm normalized name: Dental Resources brand of Stannous Fluoride Dental Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sources of self-medication
Trial: 32366238
Drug: Risk factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk factors for self-medication
Trial: 37349694
Drug: Tolvaptan treatment
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan treatment
Trial: 32166429
Drug: Leflunomide (LEF)
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide (LEF) 20 mg daily
Trial: 33693561
Drug: Ruxolitinib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (10 mg twice daily) plus stable ART for 5 weeks
Trial: 33190008
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg per day sumac powder for 12 weeks
Trial: 35972010
Drug: Topical khat
RxNorm normalized name: KHAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical khat leaves
Trial: 33753456
Drug: fam-trastuzumab deruxtecan-nxki
RxNorm normalized name: fam-trastuzumab deruxtecan-nxki
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: fam-trastuzumab deruxtecan-nxki (T-DXd) at a dose of 5.4 mg/kg
Trial: 32460697
Drug: Professional oral
RxNorm normalized name: Dentek Professional Oral Care Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional oral care intervention (weekly)
Trial: 32804611
Drug: Glucocorticoids treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids treatment in patients with initial C-reactive protein (CRP) ≥20 mg/dL
Trial: 32804611
Drug: Glucocorticoids treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids treatment in patients with CRP <10 mg/dL
Trial: 32634760
Drug: Dose-dense (DD)
RxNorm normalized name: DDS
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-dense (DD) chemotherapy
Trial: 32634760
Drug: Standard-interval (SI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-interval (SI) chemotherapy
Trial: 39141378
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg)
Trial: 36273478
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose of antenatal betamethasone
Trial: 36273478
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of antenatal betamethasone
Trial: 35658325
Drug: Minodronate 1
RxNorm normalized name: Minodronate
DrugBank: Minodronic acid (DB06548)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Minodronate 1 mg with 500 mg calcium and 200 U vitamin D3
Trial: 35658325
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 500 mg calcium and 200 U vitamin D3
Trial: 34961905
Drug: Phase III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase III liquid formulation by autoinjector (Treatment A)
Trial: 34961905
Drug: Phase I/II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I/II reconstituted lyophilizate-based formulation by syringe (Treatment C)
Trial: 34961905
Drug: Phase III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase III liquid formulation by prefilled syringe (Treatment B)
Trial: 33464993
Drug: Other drug
RxNorm normalized name: Other drugs for bile therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drug use screening
Trial: 33755582
Drug: Vi‐tetanus toxoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi‐tetanus toxoid conjugate vaccine (Typhoid Vaccine Acceleration Consortium: TyVAC)
Trial: 34278040
Drug: DualStim therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DualStim therapy with intracavernosal injection of Wharton's Jelly (WJ)
Trial: 34278040
Drug: DualStim therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DualStim therapy with saline (control)
Trial: 32833109
Drug: N-acetylcysteine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine administration prior to CA procedure
Trial: 34867116
Drug: Computer-assisted local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted local anesthesia injection
Trial: 34867116
Drug: Traditional manual
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional manual injection of local anesthesia
Trial: 35366801
Drug: EZ-bronchial blocker
RxNorm normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EZ-bronchial blocker (EZB)
Trial: 32374123
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg solifenacin succinate in the early postoperative period (G1A)
Trial: 32374123
Drug: No solifenacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No solifenacin treatment (G1B)
Trial: 32374123
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg solifenacin succinate in the early postoperative period (G2A)
Trial: 32374123
Drug: No solifenacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No solifenacin treatment (G2B)
Trial: 36097258
Drug: Topical benzyl
RxNorm normalized name: benzyl alcohol Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzyl benzoate (25% or 10%) for daily use over three consecutive days
Trial: 36097258
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin (200μg/kg body weight) twice, one week apart
Trial: 36097258
Drug: Topical benzyl
RxNorm normalized name: benzyl alcohol Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzyl benzoate (25% or 10%) upon repeated application
Trial: 36097258
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin upon repeated application
Trial: 36097258
Drug: Topical benzyl
RxNorm normalized name: benzyl alcohol Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzyl benzoate upon repeated application
Trial: 36097258
Drug: Topical benzyl
RxNorm normalized name: benzyl alcohol Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzyl benzoate
Trial: 33313736
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of self-care CIH therapies (tai chi/qi gong, yoga, meditation) and practitioner-delivered CIH therapies (chiropractic care, acupuncture, therapeutic massage)
Trial: 33313736
Drug: Practitioner-delivered CIH
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practitioner-delivered CIH therapies alone (chiropractic care, acupuncture, therapeutic massage)